{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T09:28:50Z","timestamp":1765704530279,"version":"3.37.3"},"reference-count":28,"publisher":"Informa UK Limited","issue":"9","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011725","name":"Les Laboratoires Servier","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.2217\/fon-2022-0662","type":"journal-article","created":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T14:01:58Z","timestamp":1682690518000},"page":"643-650","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["A UK cost\u2013effectiveness analysis of trifluridine\/tipiracil for heavily pretreated metastatic gastroesophageal cancers"],"prefix":"10.1080","volume":"19","author":[{"given":"Leanne","family":"Hamerton","sequence":"first","affiliation":[{"name":"Servier Laboratories Limited,\rSefton House, Sefton Park, Bells Hill, Stoke Poges,\rSlough,\rSL2 4JS,\rUK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly","family":"Gomes","sequence":"additional","affiliation":[{"name":"Servier Laboratories Limited,\rSefton House, Sefton Park, Bells Hill, Stoke Poges,\rSlough,\rSL2 4JS,\rUK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronan","family":"Fougeray","sequence":"additional","affiliation":[{"name":"Institut de Recherches Internationales Servier,\r92210Suresnes,\rFrance"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6503-2850","authenticated-orcid":false,"given":"Emma S","family":"Hook","sequence":"additional","affiliation":[{"name":"Delta Hat Limited,\rNottingham,\rNG10 3SX,\rUK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta Vargas","family":"Gomes","sequence":"additional","affiliation":[{"name":"Les Laboratoires Servier,\r92150Suresnes,\rFrance"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0026-8301","authenticated-orcid":false,"given":"Ole","family":"Hauch","sequence":"additional","affiliation":[{"name":"Les Laboratoires Servier,\r92150Suresnes,\rFrance"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7091-0972","authenticated-orcid":false,"given":"Ash","family":"Bullement","sequence":"additional","affiliation":[{"name":"Delta Hat Limited,\rNottingham,\rNG10 3SX,\rUK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2023,4,28]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw350"},{"volume-title":"Advisory board meeting minutes.","year":"2019","key":"e_1_3_5_4_1","unstructured":"Servier data on file. Advisory board meeting minutes. (2019)."},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30739-3"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.5995"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1414325"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-020-01053-9"},{"key":"e_1_3_5_10_1","unstructured":"EMA . Summary of product characteristics (SmPC): trifluridine\/tipiracil (Lonsurf). (2016). www.ema.europa.eu\/en\/documents\/product-information\/lonsurf-epar-product-information_en.pdf"},{"key":"e_1_3_5_11_1","unstructured":"Medicines & Healthcare Products Regulatory Agency . MHRA: Summary of Product Characteristics\u2013Lonsurf 15 mg\/6.14 mg film-coated tablets. (2021). https:\/\/mhraproducts4853.blob.core.windows.net\/docs\/43bcc3b79dd4ebf599d263e3a393f40689a6d972"},{"key":"e_1_3_5_12_1","unstructured":"Medicines & Healthcare products Regulatory Agency . MHRA: Summary of Product Characteristics\u2013Lonsurf 20 mg\/8.19 mg film-coated tablets (2021). https:\/\/mhraproducts4853.blob.core.windows.net\/docs\/9ddf7b44d7c62c0e902f9bc955528c68bd8db0e0"},{"key":"e_1_3_5_13_1","first-page":"1","volume-title":"Medicines Advice: Trifluridine\/Tipiracil (Lonsurf).","year":"2021","unstructured":"Medicines Advice: Trifluridine\/Tipiracil (Lonsurf). Scottish Medicines Consortium, 1\u201313 (2021). www.scottishmedicines.org.uk\/medicines-advice\/trifluridinetipiracil-lonsurf-full-smc2329\/"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2020.08.2094"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40258-019-00513-3"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clcc.2017.09.001"},{"key":"e_1_3_5_17_1","unstructured":"Working with SMC\u2013A Guide for Manufacturers . Scottish Medicines Consortium. (2021). www.scottishmedicines.org.uk\/media\/6164\/working-with-smc.pdf"},{"key":"e_1_3_5_18_1","unstructured":"PMG36: NICE Health Technology Evaluations: the Manual . National Institute for Health and Care Excellence (2022). www.nice.org.uk\/process\/pmg36\/chapter\/introduction-to-health-technology-evaluation"},{"key":"e_1_3_5_19_1","first-page":"1","volume-title":"NICE DSU Technical Support Document 14: Survival Analysis for Economic Evaluations Alongside Clinical Trials\u2013Extrapolation with Patient-Level Data.","author":"Latimer NR","year":"2011","unstructured":"Latimer NR . NICE DSU Technical Support Document 14: Survival Analysis for Economic Evaluations Alongside Clinical Trials\u2013Extrapolation with Patient-Level Data.University of Sheffield, Sheffield, UK, 1\u201352 (2011). http:\/\/nicedsu.org.uk\/wp-content\/uploads\/2016\/03\/NICE-DSU-TSD-Survival-analysis.updated-March-2013.v2.pdf"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/85.5.365"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2009.00569.x"},{"key":"e_1_3_5_22_1","unstructured":"National Health Service . Improvement 2017\/18 NHS Reference Costs (2019). https:\/\/webarchive.nationalarchives.gov.uk\/ukgwa\/20200501111106\/https:\/improvement.nhs.uk\/resources\/reference-costs\/"},{"key":"e_1_3_5_23_1","first-page":"1","volume-title":"Unit Costs of Health and Social Care.","author":"Curtis L","year":"2018","unstructured":"Curtis L , BurnsA, Personal Social Services Research Unit. Unit Costs of Health and Social Care.University of Kent, Canterbury, Kent, UK, 1\u2013201 (2018). www.pssru.ac.uk\/project-pages\/unit-costs\/unit-costs-2018\/"},{"key":"e_1_3_5_24_1","unstructured":"TA378: Ramucirumab for Treating Advanced Gastric Cancer or Gastro\u2013oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy. National Institute for Health and Care Excellence. (2016). www.nice.org.uk\/guidance\/ta378\/history"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269216315595203"},{"key":"e_1_3_5_26_1","unstructured":"Medicines Advice: Autologous Anti-CD19-transduced CD3+ Cells (KTE-X19) 0.4 to 2\u00d7108 Cells Dispersion for Infusion (Tecartus\u00ae). Scottish Medicines Consortium. Glasgow UK (2021). www.scottishmedicines.org.uk\/media\/6180\/autologous-tecartus-final-july-2021-for-website.pdf"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-022-01229-4"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737167.2021.1921576"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-019-02127-6"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyab086"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2022-0662","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:47:02Z","timestamp":1719125222000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2022-0662"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":28,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["10.2217\/fon-2022-0662"],"URL":"https:\/\/doi.org\/10.2217\/fon-2022-0662","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"type":"print","value":"1479-6694"},{"type":"electronic","value":"1744-8301"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-06-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-02","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}